The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Authors
Keywords
-
Journal
Expert Review of Neurotherapeutics
Volume 15, Issue 10, Pages 1219-1229
Publisher
Informa UK Limited
Online
2015-09-25
DOI
10.1586/14737175.2015.1086269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A brief summary of the articles appearing in this issue of Biological Psychiatry.
- (2015) BIOLOGICAL PSYCHIATRY
- Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors
- (2015) Tamaki Ishima et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator
- (2015) Noriko Yoshimi et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
- (2015) L. Citrome INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
- (2015) John M. Kane et al. SCHIZOPHRENIA RESEARCH
- The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
- (2014) J. Peuskens et al. CNS DRUGS
- Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms
- (2014) Matthias Oelke et al. Expert Opinion On Drug Safety
- New Treatment Targets to Improve Symptoms in Schizophrenia
- (2014) Leslie Citrome JOURNAL OF CLINICAL PSYCHIATRY
- Prazosin in the Treatment of PTSD
- (2014) BEN GREEN Journal of Psychiatric Practice
- Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy
- (2014) Zofia Rogóż Pharmacological Reports
- Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors
- (2014) Noriko Yoshimi et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- α2-Adrenoceptors are targets for antipsychotic drugs
- (2014) Jan Brosda et al. PSYCHOPHARMACOLOGY
- Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
- (2014) Nevena Divac et al. Biomed Research International
- Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach
- (2013) Leslie Citrome CNS DRUGS
- Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms
- (2013) Stephen M. Stahl CNS SPECTRUMS
- Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability
- (2013) Leslie Citrome Expert Opinion on Drug Metabolism & Toxicology
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes
- (2013) Glen I. Spielmans et al. PLOS MEDICINE
- Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia
- (2012) H. Y. Meltzer et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors
- (2012) Tamaki Ishima et al. PLoS One
- Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: Role played by PLC-γ, IP3 receptors
- (2011) Kanako Itoh et al. BRAIN RESEARCH
- Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties
- (2011) Adrian Newman-Tancredi et al. PSYCHOPHARMACOLOGY
- The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
- (2011) Herbert Y. Meltzer et al. PSYCHOPHARMACOLOGY
- Aripiprazole in schizophrenia and schizoaffective disorder: A review
- (2010) Emmanuel Stip et al. CLINICAL THERAPEUTICS
- If at First You Donʼt Succeed
- (2010) K. Ryan Connolly et al. DRUGS
- Potentiation of nerve growth factor-induced neurite outgrowth by the ROCK inhibitor Y-27632: A possible role of IP3 receptors
- (2010) Takahiko Minase et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
- (2010) Joanna C. Neill et al. PHARMACOLOGY & THERAPEUTICS
- A Novel Target of Action of Minocycline in NGF-Induced Neurite Outgrowth in PC12 Cells: Translation Initiation Factor eIF4AI
- (2010) Kenji Hashimoto et al. PLoS One
- Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
- (2009) Lucy Y. Wang et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making
- (2009) Jan Volavka et al. EXPERT OPINION ON PHARMACOTHERAPY
- Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor
- (2009) Britney Williams et al. JOURNAL OF NEUROCHEMISTRY
- Antipsychotic drug actions on gene modulation and signaling mechanisms
- (2009) Raffaella Molteni et al. PHARMACOLOGY & THERAPEUTICS
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP3 Receptors and Cellular Signaling Pathways
- (2008) Tomoko Nishimura et al. PLoS One
- Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors
- (2008) Tamaki Ishima et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study
- (2008) Daniel E. Casey et al. PSYCHOPHARMACOLOGY
- Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
- (2007) Yuko Fujita et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More